WO2012170017A1 - Novel formulations - Google Patents

Novel formulations Download PDF

Info

Publication number
WO2012170017A1
WO2012170017A1 PCT/US2011/039553 US2011039553W WO2012170017A1 WO 2012170017 A1 WO2012170017 A1 WO 2012170017A1 US 2011039553 W US2011039553 W US 2011039553W WO 2012170017 A1 WO2012170017 A1 WO 2012170017A1
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
chitosan
nanoparticle
nanoparticles
polymer
Prior art date
Application number
PCT/US2011/039553
Other languages
French (fr)
Inventor
Leo Rubin
Shaker Mousa
Original Assignee
Avant Garde Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avant Garde Therapeutics Inc. filed Critical Avant Garde Therapeutics Inc.
Publication of WO2012170017A1 publication Critical patent/WO2012170017A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/12Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/24Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A61K47/6937Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5161Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin

Definitions

  • the field relates to nanoparticles comprising triiodothyronine (T3), and to their use in treatment of cardiac conditions, particularly cardiac arrest and acute heart failure.
  • T3 triiodothyronine
  • Cardiac arrest refers to a state where the heart of the patient has stopped beating effectively and is no longer functioning to pump blood around the body. It is often caused by myocardial infarction. If treated promptly, cardiac arrest may sometimes reversed by cardiopulmonary resuscitation (CPR) and defibrillation. Drugs to treat cardiac arrest include epinephrine, which stimulates the heart muscle and also augments pressure in the aorta, which drives coronary perfusion. Whether epinephrine significantly improves overall survival is controversial, however, because while it may improve the chances for resuscitation, it may also cause arrhythmias and strain on the heart which increase the risk of problems in the post-resuscitation phase.
  • CPR cardiopulmonary resuscitation
  • Acute heart failure is a critical condition that is commonly seen in patients with chronic heart disease. During acute heart failure, the ability of the heart to pump blood from the lung circulation into the peripheral circulation is impaired. Cardiogenic shock is a form of shock resulting from an inadequate circulation of blood due to primary failure of the ventricles of the heart to function effectively.
  • Triiodothyronine also known as T3, is a thyroid hormone.
  • Thyroid- stimulating hormone TSH
  • T4 activates the production of thyroxine (T4) and T3.
  • T4 is converted to T3 by deiodination.
  • T3 affects a variety of body processes, including body temperature, growth, and heart rate.
  • T3 has important effects on cardiac tissue.
  • Thyroid hormones, notably T3, modulate ventricular function via genomic and non- genomic mechanisms.
  • Cardiac stress events (cardiac arrest, myocardial infarction, etc.) are associated with steep reductions in serum T3 levels. Post resuscitation T3
  • T3 additionally has cardiostimulatory properties: it increases the cardiac output by increasing the heart rate and force of contraction. Overall, there is reason to believe that early bolus T3 injection could increase chances of resuscitating cardiac arrest victims, and that elevating T3 serum concentration could increase prospects of survival to hospital discharge.
  • T3 is not currently approved for this indication, however, and current formulations of T3 are not well suited for this purpose.
  • Triostat® requires refrigeration, making it somewhat impractical for emergency use. Also, the concentration is low for what is needed to treat cardiac arrest.
  • T3-albumin formulation have been described but are difficult to make, and like Triostat®, have poor stability and are poorly suited for quick administration in an emergency setting.
  • the invention provides T3 nanoparticles, wherein the T3 is encapsulated or immobilized by a bioabsorbable polymer, for example, having any of the following characteristics
  • the polymer comprises chitosan.
  • the polymer comprises poly(lactic-co-glycolic acid) (PLGA) or polylactic acid (PLA), e.g., PLGA having 50/50 co-polymerization of D,L-lactic acid and glycolic acid.
  • PLGA poly(lactic-co-glycolic acid)
  • PLA polylactic acid
  • the polymer comprises chitosan crosslinked using glutaraldehyde.
  • the polymer comprises chitosan linked to bile acids.
  • the polymer comprises chitosan linked to PLGA, e.g., using glutaraldehyde as crosslinker.
  • nanoparticles have a zeta potential of
  • the T3 is covalently linked to the bioabsorbable polymer, for example via the hydroxy on the phenyl moiety.
  • Such compositions can be formed using activated T3 which is activated at the phenolic hydroxy with a suitable linker and protected at the amino moiety.
  • activated T3 is formed using the synthesis as shown in Figure 9.
  • the amino- protected T3 is then linked to the nanoparticle, for example via the phenolic hydroxy, e.g. by using an activated linker group, for example a moiety capable of coupling to an amine group on the bioabsorbable polymer, for example the amino moieties on chitosan.
  • the invention provides activated T3 which is substituted on the phenolic hydroxy group with an epoxide moiety of formula [CH2-0-CH]-[CH2] tract- and which is amino protected.
  • the invention provides a compound of formula 1 :
  • n is an integer selected from 1 through 5
  • R is an amino protecting group, e.g., butoxycarbonyl (BOC).
  • X is halogen, e.g. bromine, e.g. according to a synthesis as shown in figure 10.
  • the resulting compound is then, if necessary, selectively deprotected to release the carboxy moiety, for example,
  • the activated T3 is then attached to the bioabsorbable polymer, for example, T3 having an epoxy linker moiety and an amino-protecting group is reacted with a bioabsorbable polymer having amino groups, then deprotected to provide a nanoparticle covalently linked to T3, e.g., as shown in figure 1 1.
  • This reaction may be carried out in the presence of a stabilizer, such as polyvinyl alcohol, e.g. PVA 1 % w/v, in an appropriate solvent, for example dimethylsulfoxide, e.g. DMSO (0.1 %v/v) and acetic acid (0.1 % v/v), which solvents are removed afterwards by dialysis.
  • a stabilizer such as polyvinyl alcohol, e.g. PVA 1 % w/v
  • an appropriate solvent for example dimethylsulfoxide, e.g. DMSO (0.1 %v/v) and acetic acid (0.1 % v/v), which
  • the number of T3 moieties attached to the nanoparticle may vary based on the reaction conditions and amount of reactant used, but if these condisions are kept constant, the distribution of variation will be low.
  • the nanoparticle will comprise 20 - 200 T3 moieties, e.g., about 50 per nanoparticle.
  • the amount of T3 in a batch can be assayed, e.g., as described below, by separating the nanoparticles by filtration or centrufugation, weighing, degrading the T3 nanoparticle in strong base, and measuring by HPLC.
  • the T3 nanoparticles are made from T3 and the following components:
  • the nanoparticles have these components in approximately the following amounts:
  • the invention provides a method for treating a cardiac condition, e.g. cardiac arrest, cardiac arrhymia, or cardiac insufficiency, comprising administering an effective amount of a T3-nanoparticle to a patient in need thereof, wherein the T3-nanoparticle comprises a bioabsorbable polymer, for example as described above.
  • a cardiac condition e.g. cardiac arrest, cardiac arrhymia, or cardiac insufficiency
  • the T3-nanoparticle administered comprises a chitosan-PLGA nanoparticles encapsulating T3.
  • the T3-nanoparticIe administered comprises chitosan nanoparticles encapsulating T3 with glutaraldehyde as a cross linker.
  • Other cross-linkers may be used.
  • the T3-nanoparticle administered comprises chitosan-PLGA nanoparticles encapsulating T3 alone.
  • Such examples of T3 nanoparticles may utilize a process that includes gelation/conjugation of preformed biodegradable polymers.
  • the T3-nanoparticle administered includes chitosan-PLGA nanoparticles immobilizing T3.
  • the T3- nanoparticles administered comprises chitosan-PLGA nanoparticies immobilizing T3 as well as chitosan-PLGA nanoparticies encapsulating T3.
  • the T3-nanoparticle comprises T3 covalently linked to chitosan or chitosan-PLGA nanoparticies.
  • Figure I depicts a schematic flowchart of various methods of synthesizing T3-nanoparticles.
  • Figure 2, 2A and 2B shows an example of a flowchart of PLGA- Chitosan nanoparticies encapsulating T3.
  • Figures 3A and 3B show a size measurement of T3 encapsulated
  • PLGA-nanoparticles with and without a cross-linker.
  • Figures 4A and 4B depict zeta potential measurements of T3- nanoparticles.
  • Figure 5 A and 5B shows various measurements for T3-nanoparticles.
  • Figure 6 depicts the kinetics of T3 nano formulations.
  • Figures 7A, 7B and 7C show other examples of kinetics of T3 nanoformulations.
  • Figure 8A shows one example of blood levels of T3 using T3- nanoparticies and T3 alone in mice.
  • Figure 8B shows another example of blood levels of T3 using T3 nanoparticies and T3 alone in mice.
  • Figure 9 shows one embodiment of the synthesis of amino-protected
  • FIG. 1 1 shows one example of activated T3 attached to the bioabsorbable polymer, for example, T3 having an epoxy linker moiety and an amino- protecting group is reacted with a bioabsorbable polymer having amino groups, then deprotected to provide a nanoparticle covalently linked to T3.
  • FIG. 12 shows one example of T3 attached to the bioabsorbable polymer.
  • the methods using the T3 nanoparticles may be use to treat acute cardiac insufficiency.
  • cardiac conditions include cardiac arrest, cardiogenic shock, and acute heart failure.
  • T3-nanoparticles may act rapidly and directly increase the effective mechanical contraction of the heart, decrease systemic vascular resistance, and increase heart rate.
  • the particles provide a sustained release which allows the T3 to affect gene expression.
  • the T3 is covalently linked to the bioabsorbable polymer, which reduces the genomic effect and enhances the effect on the integrin receptor.
  • the T3 nanoparticles of the invention may be administered in conjunction with, or adjunctive to, the normal standard of care for cardiac arrest, e.g., cardiopulmonary resuscitation, defibrillation, and epinephrine. They may be administered shortly after the cardiac arrest, and optionally later, e.g., 8-24 hours later, to preserve cardiac function.
  • cardiac arrest e.g., cardiopulmonary resuscitation, defibrillation, and epinephrine.
  • They may be administered shortly after the cardiac arrest, and optionally later, e.g., 8-24 hours later, to preserve cardiac function.
  • a single emulsion process may produce chitosan-PLGA nanoparticles encapsulating T3.
  • a process involving gelation/conjugation of preformed biodegradable polymers produces 1 ) chitosan nanoparticles
  • cross-linker encapsulating T3 with and without glutaraldehyde as a cross-linker; or 2) chitosan- PLGA nanoparticles encapsulating T3.
  • Other cross-linkers may be used.
  • a process involving chemical bonding of T3 on the surface of chitosan-PLGA nanoparticles produces 1 ) chitosan-PLGA nanoparticles immobilizing T3 or 2) chitosan-PLGA nanoparticles immobilizing T3 and additionally including chitosan-PLGA nanoparticles encapsulating T3.
  • Chitosan nanoparticles encapsulating T3 Chitosan nanoparticles encapsulating T3.
  • PLGA and T3 are first immersed in a 1 % PVA solution and chitosan. They are then stirred and sonicated. Then a dialysis step is performed. After a dialysis step occurs, PLGA-chitosan nanoparticles encapsulating T3 are produced. Then in the final step, the nanoparticles may then have a chitosan layer cross-linked with glutaraldehyde. Other cross-linkers may be used.
  • FIGS 3A and 3B T3 nanoformulations produced by the gelation/conjugation process are further characterized.
  • Figure 3A shows a size measurement of T3 encapsulated PLGA-chitosan nanoparticles by DLS.
  • Figure 3B shows a size measurement of T3 encapsulated PLGA- chitosan nanoparticles by DLS and including glutaraldehyde as a cross-linker.
  • Other cross-linkers known in the art may be utilized.
  • FIG. 4A a zeta potential measurement of T3 encapsulated PLGA- chitosan nanoparticles by DLS is shown.
  • Figure 4B shows a zeta potential measurement of T3 encapsulated PLGA-nanoparticles by DLS.
  • glutaraldehyde was used as a cross-linker.
  • the accompanying table shows that the zeta potential for the nanoparticles decreases when glutaraldehyde was used as a cross-linker.
  • An entrapment efficiency may also be measured.
  • the entrapment efficiency may be calculated to be the total amount of T3 in the nanoparticles/initial concentration of T3 added to make the formulation x 100.
  • the entrapment efficiency for a chitosan-PLGA-T3 nanoparticle is 82%.
  • the entrapment efficiency for a chitosan-PLGA-T3 that is cross-linked with glutaraldehyde is only 20%. Thus, adding a cross-linker to the nanoparticles decreases the entrapment efficiency.
  • Figure 7A depicts a typical MRM chromatogram of T3 and DIPTA assayed by the LC-MS/MS method. The conditions are described as follows:
  • Mobile phase are as follows: 70% 10 mM ammonium acetate, pH of 4.0;
  • a detect limit of T3 37.5 pg in 15 ⁇ may be detected
  • An extraction efficiency of 85% may be achieved in one example.
  • Figure 7B depicts a MRM chromatogram of a T3 standard assayed by LC-MS/MS method.
  • Figure 7C shows a calibration curve of T3 standard assayed by LC/MS/MS method. The calibration curve includes 1.56-400 ng/ml of a T3 standard.
  • FIG 8A the figure shows that greater amount of T3 remained in the blood after time when a T3 nanoparticle comprising a PLGA-chitosan-glutaraldehyde nanoparticle was used.
  • This T3-nanoparticle is administered intraperitoneal ly in mice.
  • Administration routes include, but not limited to intravenous, intracardiac, subcutaneous, intramuscular, orally and intrapulmonary.
  • the methods allow for delivery of T3 in a few minutes and provide sustained elevated serum concentration of T3 over time.
  • the T3 -nanoparticles may be lyophilized.
  • the nanoparticles are stable with long shelf life.
  • the T3-nanoparticles may be dispensable in physiological saline.
  • the formulations may for example have a pH of 7.0-7.8, e.g., 7.4.
  • T3-nanoparticles The size and surface charge of the T3-nanoparticles may be manipulated.
  • the following formulations of nanoparticles comprising T3 covalently bonded to chitosan are prepared:
  • nanoparticles are shown to be stable over three months and do not show significant aggregation in solution.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nanotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Nanoparticles comprising T3 and their use in treating, e.g., cardiac conditions, for example cardiac arrest, are provided. Such nanoparticles provide improved delivery of T3 and allow for acute treatment and optionally for sustained release of T3 in a patient.

Description

NOVEL FORMULATIONS
This application claims the benefit of US Provisional Application 61/184,903 filed June 8, 2009, and US Provisional Application 61/248, 127, filed October 2, 2009, the contents of each of which are incorporated herein by reference.
TECHNICAL FIELD
[0001] The field relates to nanoparticles comprising triiodothyronine (T3), and to their use in treatment of cardiac conditions, particularly cardiac arrest and acute heart failure.
BACKGROUND OF THE INVENTION
[0002] Cardiac arrest refers to a state where the heart of the patient has stopped beating effectively and is no longer functioning to pump blood around the body. It is often caused by myocardial infarction. If treated promptly, cardiac arrest may sometimes reversed by cardiopulmonary resuscitation (CPR) and defibrillation. Drugs to treat cardiac arrest include epinephrine, which stimulates the heart muscle and also augments pressure in the aorta, which drives coronary perfusion. Whether epinephrine significantly improves overall survival is controversial, however, because while it may improve the chances for resuscitation, it may also cause arrhythmias and strain on the heart which increase the risk of problems in the post-resuscitation phase.
[0003] Other forms of acute cardiac insufficiency include acute heart failure and cardiogenic shock. Acute heart failure is a critical condition that is commonly seen in patients with chronic heart disease. During acute heart failure, the ability of the heart to pump blood from the lung circulation into the peripheral circulation is impaired. Cardiogenic shock is a form of shock resulting from an inadequate circulation of blood due to primary failure of the ventricles of the heart to function effectively.
[0004] Triiodothyronine, also known as T3, is a thyroid hormone. Thyroid- stimulating hormone (TSH) activates the production of thyroxine (T4) and T3. T4 is converted to T3 by deiodination. T3 affects a variety of body processes, including body temperature, growth, and heart rate. T3 has important effects on cardiac tissue. Thyroid hormones, notably T3, modulate ventricular function via genomic and non- genomic mechanisms. Cardiac stress events (cardiac arrest, myocardial infarction, etc.) are associated with steep reductions in serum T3 levels. Post resuscitation T3
I level correlates highly with survival rate. T3 additionally has cardiostimulatory properties: it increases the cardiac output by increasing the heart rate and force of contraction. Overall, there is reason to believe that early bolus T3 injection could increase chances of resuscitating cardiac arrest victims, and that elevating T3 serum concentration could increase prospects of survival to hospital discharge.
[0005] T3 is not currently approved for this indication, however, and current formulations of T3 are not well suited for this purpose. Triostat® requires refrigeration, making it somewhat impractical for emergency use. Also, the concentration is low for what is needed to treat cardiac arrest. T3-albumin formulation have been described but are difficult to make, and like Triostat®, have poor stability and are poorly suited for quick administration in an emergency setting.
SUMMARY OF THE INVENTION
[0006] The invention provides T3 nanoparticles, wherein the T3 is encapsulated or immobilized by a bioabsorbable polymer, for example, having any of the following characteristics
a. Wherein the polymer comprises chitosan.
b. Wherein the polymer comprises poly(lactic-co-glycolic acid) (PLGA) or polylactic acid (PLA), e.g., PLGA having 50/50 co-polymerization of D,L-lactic acid and glycolic acid.
c. Wherein the polymer comprises chitosan crosslinked using glutaraldehyde.
d. Wherein the polymer comprises chitosan linked to bile acids. e. Wherein the polymer comprises chitosan linked to PLGA, e.g., using glutaraldehyde as crosslinker.
f. Any of the foregoing wherein the nanoparticles have an average
diameter of 50-1000 nm, e.g., 100-500 nm or 50-250 nm. g- Any of the foregoing wherein the nanoparticles have a zeta potential of
10- 100 mV.
h. Any of the foregoing wherein the nanoparticle comprises a second pharmacologically active ingredient. [0007] In one embodiment, the T3 is covalently linked to the bioabsorbable polymer, for example via the hydroxy on the phenyl moiety. Such compositions can be formed using activated T3 which is activated at the phenolic hydroxy with a suitable linker and protected at the amino moiety. For example, in one embodiment, amino-protected T3 is formed using the synthesis as shown in Figure 9. The amino- protected T3 is then linked to the nanoparticle, for example via the phenolic hydroxy, e.g. by using an activated linker group, for example a moiety capable of coupling to an amine group on the bioabsorbable polymer, for example the amino moieties on chitosan.
[0008] In one embodiment, therefore, the invention provides activated T3 which is substituted on the phenolic hydroxy group with an epoxide moiety of formula [CH2-0-CH]-[CH2]„- and which is amino protected. For example, the invention provides a compound of formula 1 :
Figure imgf000004_0001
Formula 1
wherein n is an integer selected from 1 through 5, and R is an amino protecting group, e.g., butoxycarbonyl (BOC).
[0009] The T3 may thus be activated, for example using an epoxyalkyl of formula [CH2-0-CH]-[CH2]„-X wherein n= l -5 and X is halogen, e.g. bromine, e.g. according to a synthesis as shown in figure 10. The resulting compound is then, if necessary, selectively deprotected to release the carboxy moiety, for example,
Figure imgf000004_0002
Dipropyleneoxide-Boc-T3 2.5 N NaOH, overnight
Figure imgf000005_0001
to provide T3 which is activated at the phenolic hydroxy (here, with propylene oxide) and amino-protected (here, with BOC).
[0010] The activated T3 is then attached to the bioabsorbable polymer, for example, T3 having an epoxy linker moiety and an amino-protecting group is reacted with a bioabsorbable polymer having amino groups, then deprotected to provide a nanoparticle covalently linked to T3, e.g., as shown in figure 1 1. This reaction may be carried out in the presence of a stabilizer, such as polyvinyl alcohol, e.g. PVA 1 % w/v, in an appropriate solvent, for example dimethylsulfoxide, e.g. DMSO (0.1 %v/v) and acetic acid (0.1 % v/v), which solvents are removed afterwards by dialysis. The number of T3 moieties attached to the nanoparticle may vary based on the reaction conditions and amount of reactant used, but if these condisions are kept constant, the distribution of variation will be low. Typically, the nanoparticle will comprise 20 - 200 T3 moieties, e.g., about 50 per nanoparticle. The amount of T3 in a batch can be assayed, e.g., as described below, by separating the nanoparticles by filtration or centrufugation, weighing, degrading the T3 nanoparticle in strong base, and measuring by HPLC.
[0011J The overall scheme may be for example as shown in figure 12.
[0012] In one example, the T3 nanoparticles are made from T3 and the following components:
Figure imgf000005_0002
Chitosan
Figure imgf000005_0003
Figure imgf000006_0001
PVA (stabilizer). In one example, the nanoparticles have these components in approximately the following amounts:
Figure imgf000006_0002
The contents of the nanoparticles are confirmed using, e.g. HPLC and LC/MS. The nanoparticle formulations may be sterilized using conventional means, e.g., filtration, gamma radiation. [0013] In one embodiment, the invention provides a method for treating a cardiac condition, e.g. cardiac arrest, cardiac arrhymia, or cardiac insufficiency, comprising administering an effective amount of a T3-nanoparticle to a patient in need thereof, wherein the T3-nanoparticle comprises a bioabsorbable polymer, for example as described above.
[0014] In a specific example of the method, the T3-nanoparticle administered comprises a chitosan-PLGA nanoparticles encapsulating T3.
[0015] In another example, the T3-nanoparticIe administered comprises chitosan nanoparticles encapsulating T3 with glutaraldehyde as a cross linker. Other cross-linkers may be used. In yet another example, the T3-nanoparticle administered comprises chitosan-PLGA nanoparticles encapsulating T3 alone. Such examples of T3 nanoparticles may utilize a process that includes gelation/conjugation of preformed biodegradable polymers.
[0016] In yet another example, the T3-nanoparticle administered includes chitosan-PLGA nanoparticles immobilizing T3. Alternatively, the T3- nanoparticles administered comprises chitosan-PLGA nanoparticies immobilizing T3 as well as chitosan-PLGA nanoparticies encapsulating T3.
[0017] In another example, the T3-nanoparticle comprises T3 covalently linked to chitosan or chitosan-PLGA nanoparticies.
BRIEF DESCRIPTION OF THE FIGURES
(0018] Figure I depicts a schematic flowchart of various methods of synthesizing T3-nanoparticles.
[0019] Figure 2, 2A and 2B shows an example of a flowchart of PLGA- Chitosan nanoparticies encapsulating T3.
[0020] Figures 3A and 3B show a size measurement of T3 encapsulated
PLGA-nanoparticles with and without a cross-linker.
[0021] Figures 4A and 4B depict zeta potential measurements of T3- nanoparticles.
[0022] Figure 5 A and 5B shows various measurements for T3-nanoparticles.
[0023] Figure 6 depicts the kinetics of T3 nano formulations.
[0024] Figures 7A, 7B and 7C show other examples of kinetics of T3 nanoformulations.
[0025] Figure 8A shows one example of blood levels of T3 using T3- nanoparticies and T3 alone in mice.
[0026] Figure 8B shows another example of blood levels of T3 using T3 nanoparticies and T3 alone in mice.
[0027] Figure 9 shows one embodiment of the synthesis of amino-protected
T3.
[0028] Figure 10 shows one method in which T3 may thus be activated, for example using an epoxyalkyl of formula [CH2-0-CH]-[CH2]n-X wherein n=I-5 and X is halogen, e.g. bromine.
[0029] Figure 1 1 shows one example of activated T3 attached to the bioabsorbable polymer, for example, T3 having an epoxy linker moiety and an amino- protecting group is reacted with a bioabsorbable polymer having amino groups, then deprotected to provide a nanoparticle covalently linked to T3.
[0030] Figure 12 shows one example of T3 attached to the bioabsorbable polymer. DETAILED DESCRIPTION
[0031] The examples and drawings provided in the detailed description are merely examples, which should not be used to limit the scope of the claims in any claim construction or interpretation.
[0032] The methods using the T3 nanoparticles may be use to treat acute cardiac insufficiency. Examples of cardiac conditions that may be treated include cardiac arrest, cardiogenic shock, and acute heart failure.
[0033] For example, while not bound by theory, it is believed that delivery of
T3-nanoparticles may act rapidly and directly increase the effective mechanical contraction of the heart, decrease systemic vascular resistance, and increase heart rate.
[0034] In one embodiment, the particles provide a sustained release which allows the T3 to affect gene expression. In another embodiment, the T3 is covalently linked to the bioabsorbable polymer, which reduces the genomic effect and enhances the effect on the integrin receptor.
[0035] The T3 nanoparticles of the invention may be administered in conjunction with, or adjunctive to, the normal standard of care for cardiac arrest, e.g., cardiopulmonary resuscitation, defibrillation, and epinephrine. They may be administered shortly after the cardiac arrest, and optionally later, e.g., 8-24 hours later, to preserve cardiac function.
[0036] Various methods of synthesizing T3-nanoparticles are provided. For example, a single emulsion process may produce chitosan-PLGA nanoparticles encapsulating T3. In yet another example, a process involving gelation/conjugation of preformed biodegradable polymers produces 1 ) chitosan nanoparticles
encapsulating T3 with and without glutaraldehyde as a cross-linker; or 2) chitosan- PLGA nanoparticles encapsulating T3. Other cross-linkers may be used.
[0037] In yet another example, a process involving chemical bonding of T3 on the surface of chitosan-PLGA nanoparticles produces 1 ) chitosan-PLGA nanoparticles immobilizing T3 or 2) chitosan-PLGA nanoparticles immobilizing T3 and additionally including chitosan-PLGA nanoparticles encapsulating T3.
[0038] In Figure 2, a flowchart shows an example of synthesis of PLGA-
Chitosan nanoparticles encapsulating T3. In this example, PLGA and T3 are first immersed in a 1 % PVA solution and chitosan. They are then stirred and sonicated. Then a dialysis step is performed. After a dialysis step occurs, PLGA-chitosan nanoparticles encapsulating T3 are produced. Then in the final step, the nanoparticles may then have a chitosan layer cross-linked with glutaraldehyde. Other cross-linkers may be used.
[0039] In Figures 3A and 3B, T3 nanoformulations produced by the gelation/conjugation process are further characterized. Figure 3A shows a size measurement of T3 encapsulated PLGA-chitosan nanoparticles by DLS.
[0040] Figure 3B shows a size measurement of T3 encapsulated PLGA- chitosan nanoparticles by DLS and including glutaraldehyde as a cross-linker. Other cross-linkers known in the art may be utilized.
[0041] In Figure 4A, a zeta potential measurement of T3 encapsulated PLGA- chitosan nanoparticles by DLS is shown. Figure 4B shows a zeta potential measurement of T3 encapsulated PLGA-nanoparticles by DLS. In this case, glutaraldehyde was used as a cross-linker. The accompanying table shows that the zeta potential for the nanoparticles decreases when glutaraldehyde was used as a cross-linker.
[0042] In Figure 5, amounts of PLGA, chitosan, and PVA are shown. In addition, a relevant ph value, a particle size, a type of distribution, and a zeta potential are shown. A ratio of PLGA to chitosan is described. Also, a process of forming nanoparticles using PLGA and chitosan is shown.
[0043] In Figure 6, kinetics of T3-nanoformulations are described. As the concentration of T3 increases, a peak area increases linearly.
[0044] Additionally, a loading level of T3 in a nanoparticle formulation measured by a HPLC method, are shown below as follows.
[0045]
Batch # Treatment T3 conn, (ug/ml) add 1 M NaOH, 2
051 109-1 82.18
hour add 1 M NaOH, 2
051 109-3 19.89
hour directly diluted w/o
109-1
NaOH
directly diluted w/o
051 109-3 19.77
NaOH
[0046] An entrapment efficiency may also be measured. The entrapment efficiency may be calculated to be the total amount of T3 in the nanoparticles/initial concentration of T3 added to make the formulation x 100. For example, the entrapment efficiency for a chitosan-PLGA-T3 nanoparticle is 82%. The entrapment efficiency for a chitosan-PLGA-T3 that is cross-linked with glutaraldehyde is only 20%. Thus, adding a cross-linker to the nanoparticles decreases the entrapment efficiency.
[0047] In Figures 7A-7C, other examples of kinetics of T3 nanoformulations are shown.
[0048] Figure 7A depicts a typical MRM chromatogram of T3 and DIPTA assayed by the LC-MS/MS method. The conditions are described as follows:
LC-MS/MS conditions for T3 assay:
Column: C I 8, Waters Sunfire, 100 mm, at 40 °C ;
Mobile phase are as follows: 70% 10 mM ammonium acetate, pH of 4.0;
T3: 649.8-448 m/z;
DITPA (as internal standard):508.8-381.9 m/z;
A detect limit of T3 : 37.5 pg in 15 μΐ may be detected;
An extraction efficiency of 85% may be achieved in one example.
Figure 7B depicts a MRM chromatogram of a T3 standard assayed by LC-MS/MS method. Figure 7C shows a calibration curve of T3 standard assayed by LC/MS/MS method. The calibration curve includes 1.56-400 ng/ml of a T3 standard.
In Figure 8A, the figure shows that greater amount of T3 remained in the blood after time when a T3 nanoparticle comprising a PLGA-chitosan-glutaraldehyde nanoparticle was used. This T3-nanoparticle is administered intraperitoneal ly in mice.
This result is in contrast with results from mice administered intraperioteneally with free T3. A lesser amount of T3 remains over time in mice administered with free T3 alone.
In Figure 8B, the intraperitoneal injection of a T3 nanoparticle comprising PLGA- chitosan-glutaraldehyde results in increased levels emerging in the bloodstream of mice. By contrast, mice injected with free T3 have increased T3 blood levels which were followed by a subsequent leveling off.
[0049] Administration routes include, but not limited to intravenous, intracardiac, subcutaneous, intramuscular, orally and intrapulmonary.
[0050] The methods allow for delivery of T3 in a few minutes and provide sustained elevated serum concentration of T3 over time.
[0051] In one example of the method, the T3 -nanoparticles may be lyophilized. The nanoparticles are stable with long shelf life. The T3-nanoparticles may be dispensable in physiological saline. The formulations may for example have a pH of 7.0-7.8, e.g., 7.4.
[0052] The size and surface charge of the T3-nanoparticles may be manipulated. For example, the following formulations of nanoparticles comprising T3 covalently bonded to chitosan are prepared:
[0053]
Figure imgf000012_0001
[0054] The nanoparticles are shown to be stable over three months and do not show significant aggregation in solution.
[0055] Alternative combinations and variations of the examples provided will become apparent based on this disclosure. It is not possible to provide specific examples for all of the many possible combinations and variations of the
embodiments described, but such combinations and variations may be claims that eventually issue.
I I

Claims

1. A formulation comprising T3 nanoparticles, wherein the T3 nanoparticle
comprises T3 encapsulated or immobilized on a bioabsorbable polymer.
2. The formulation of claim 1 wherein the polymer comprises chitosan.
3. The formulation of claim 1 or 2 wherein the polymer comprises poly(lactic-co- glycolic acid) (PLGA).
4. The formulation of claim 1 , 2 or 3 wherein the polymer comprises chitosan
crosslinked using glutaraldehyde.
5. The formulation of any of the foregoing claims wherein the polymer comprises chitosan linked to bile acids.
6. The formulation of any of the foregoing claims wherein the polymer comprises chitosan linked to PLGA, e.g., using glutaraldehyde as crosslinker.
7. The formulation of any of the foregoing claims wherein the nanoparticles have an average diameter of 50- 1000 nm, e.g., 100-500 nm, or 50-100 nm.
8. The formulation of any of the foregoing claims wherein the nanoparticles have a zeta potential of 10- 100 mV.
9. The formulation of any of the foregoing claims wherein the nanoparticle
comprises a second pharmacologically active ingredient.
10. The formulation of any of the foregoing claims comprising T3 which is not
covalently bound to the polymer.
1 1. The formulation of any of the foregoing claims comprising T3 which is covalently bound to the polymer.
12. The formulation of any of the foregoing claims comprising both T3 which is not covalently bound to the polymer and T3 which is covalently bound to the polymer.
13. A composition comprising T3 covalently linked to chitosan.
14. The composition of claim 13 wherein the linkage is between the amino groups on the chitosan and the phenolic hydroxy on the T3.
15. A method of making a T3 nanoparticle, comprising:
providing PLGA and T3;
immersing the PLGA and T3 in a 1% solution including chitosan; stirring and sonicating; and
performing a dialysis step, to yield the T3 nanoparticle.
16. The method of claim 15, further comprising a step of crosslinking a chitosan layer formed in the T3-nanoparticle, with a cross-linker.
17. The method of claim 16, wherein the step of crosslinking utilizes glutaraldehyde as the cross-linker.
18. T3 nanoparticle obtained or obtainable by the methods of any of claims 15 - 17.
19. Activated T3 of formula 1 :
Figure imgf000014_0001
wherein n is an integer selected from I through 5, and R is an amino protecting group.
20. Activated T3 according to claim 20 having the structure:
Figure imgf000014_0002
.
21. Method of making a T3 nanoparticle comprising covalently linking T3 to a
bioabsorbable polymer.
22. Method of claim 21 comprising reacting an activated T3 according to claim 19 or 20 with a bioabsorbable polymer having amino moieties, and deprotecting the product.
23. Method of claim 22 wherein the bioabsorbable polymer comprises chitosan, wherein the chitosan is optionally crosslinked, e.g., using glutaraldehyde, e.g., and/or linked to to bile acids and/or linked to poly(lactic-co-glycolic acid).
24. Method of claim 21 , 22, 23, or 24 comprising covalently linking T3 to the surface of a nanoparticle prepared according to any of claims 15-17.
25. T3 nanoparticle obtained or obtainable by the method of claim 21, 22, or 23.
26. A method for treating a cardiac condition, comprising administering an effective amount of a formulation, composition or T3 nanoparticle according to any of claims 1-14, 18 or 23, to a patient in need thereof.
27. The method of claim 26, wherein the cardiac condition is cardiac arrest.
28. The method of claim 26 wherein the cardiac condition is pulseless electrical activity.
PCT/US2011/039553 2011-06-08 2011-06-08 Novel formulations WO2012170017A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79627311A 2011-06-08 2011-06-08
US12/796,273 2011-06-08

Publications (1)

Publication Number Publication Date
WO2012170017A1 true WO2012170017A1 (en) 2012-12-13

Family

ID=47296326

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/039553 WO2012170017A1 (en) 2011-06-08 2011-06-08 Novel formulations

Country Status (1)

Country Link
WO (1) WO2012170017A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9381255B2 (en) 2009-06-08 2016-07-05 Avant Garde Therapeutics And Technologies Llc Formulations comprising T3 nanoparticles
CN114786482A (en) * 2019-11-10 2022-07-22 普鲁-阿尔医疗技术公司 Novel formulations and methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008051291A2 (en) * 2006-04-11 2008-05-02 Ordway Research Institute Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US20080200434A1 (en) * 2006-09-14 2008-08-21 Daniloff George Y Chemical Target-Binding Compositions
US20080213354A1 (en) * 2004-10-05 2008-09-04 Hsing-Wen Sung Nanoparticles for protein drug delivery
US20090022806A1 (en) * 2006-12-22 2009-01-22 Mousa Shaker A Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080213354A1 (en) * 2004-10-05 2008-09-04 Hsing-Wen Sung Nanoparticles for protein drug delivery
WO2008051291A2 (en) * 2006-04-11 2008-05-02 Ordway Research Institute Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US20080200434A1 (en) * 2006-09-14 2008-08-21 Daniloff George Y Chemical Target-Binding Compositions
US20090022806A1 (en) * 2006-12-22 2009-01-22 Mousa Shaker A Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9381255B2 (en) 2009-06-08 2016-07-05 Avant Garde Therapeutics And Technologies Llc Formulations comprising T3 nanoparticles
CN114786482A (en) * 2019-11-10 2022-07-22 普鲁-阿尔医疗技术公司 Novel formulations and methods
EP4054328A4 (en) * 2019-11-10 2023-12-13 Pro-Al Medico-Technologies, Inc. Novel formulations and methods

Similar Documents

Publication Publication Date Title
US9381255B2 (en) Formulations comprising T3 nanoparticles
Simos et al. Trends of nanotechnology in type 2 diabetes mellitus treatment
US7025991B2 (en) Drug targeting system, method of its preparation and its use
US6706289B2 (en) Methods and compositions for enhanced delivery of bioactive molecules
TWI235655B (en) Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
AU2015208699B2 (en) Nanoencapsulation of hydrophilic active compounds
CN108186575A (en) It is a kind of based on eutectic solvent be solvent embedding system
EP2679227B1 (en) Nanoparticle containing prostaglandin i2 derivative
CN1897975A (en) Nanoparticle compositions of water-soluble drugs for oral administration and preparation methods thereof
TWI572369B (en) Development of ph-responsive nanoparticles and use of ph-responsive nanoparticles for preparing enhanced tumor permeation and uptake of anticancer drugs
Yan et al. In vivo biodistribution for tumor targeting of 5-fluorouracil (5-FU) loaded N-succinyl-chitosan (Suc-Chi) nanoparticles
CN103316352A (en) Graphene oxide nano-drug carrier and anti-tumor drug as well as preparation method of anti-tumor drug
WO2012170017A1 (en) Novel formulations
CN109303768A (en) A kind of preparation method for the pH responsiveness amphipathic copolymer micella loading laccol
CN111956609A (en) Immune checkpoint blockade polypeptide prodrug nano micelle and preparation method and application thereof
CN103142489B (en) Human alpha-atrial natriuretic peptide sustained release microsphere preparation and preparation method thereof
US20130337053A1 (en) Novel formulations and methods
US20230018014A1 (en) Novel compounds and formulations
US20140328933A1 (en) Novel formulations and methods
CN116763718A (en) Paclitaxel nanocrystalline thermosensitive gel, and preparation method and application thereof
CN113101278A (en) Targeting nanoparticles with GSH and esterase tumor microenvironment dual responses and preparation method and application thereof
KR20010013745A (en) Drug targeting system, method of its preparation and its use
WO2017134655A1 (en) Improved oral absorption of octreotide and salts thereof
JPH09301865A (en) Medicine composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11867391

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11867391

Country of ref document: EP

Kind code of ref document: A1